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Evaluating Controlled Substance Documentation in an Electronic Medical Record
Abstract
The Centers for Disease Control and Prevention (CDC) directives issued in 2016 gave
guidelines for safely prescribing opiates; however, primary source discussions about
methods used for documenting opioid and controlled substance monitoring within an
electronic medical record (EMR) are limited (Hussain, Nelson, Polston & Zheng, 2019).
This leaves individual providers to determine the appropriate way to document.
Inconsistent documentation may not protect providers or organizations from regulatory,
civil or criminal liability. As stated by Raveesh, Nayak & Kumbar (2016), “The best way
to handle medico-legal issues is by preventing them”. Even with the advent and
widespread use of EMRs, documentation is still often limited to basics: diagnosis,
medication, dosage, procedures, referrals, and follow up (Schneider, 2014). The purpose
of this project was to implement a practice improvement change which included creation
of a standardized template and a central location for documentation of controlled
substance monitoring. This allowed providers to document, see the dates and results for
urine drug screens (UDS) or pill counts, review any concurrent schedule II or III
medications, and log prescription drug monitoring database (PDMD) checks. Data
indicated an improvement in documentation frequency for UDS and PDMD checks at
both 30 and 60 days; however, this increase was only statistically significant for UDS at
30 days with p = 0.004. The increase was not found to be statistically significant for
either UDS or PDMD checks at 60 days.

CONTROLLED SUBSTANCE DOCUMENTATION

3

Introduction
The state of the science for opioid use in primary care is publicly being debated
on a frequent basis. Proof of this is available every time we turn on the news or view our
social media accounts; there are numerous individuals, families, and healthcare providers
sharing how opioid addiction and substance abuse impacts them daily (Green, 2017).
Opioid overdoses have become so commonplace that many states now permit laypersons
to carry the injectable opiate antagonist, Narcan (National Institute on Drug Abuse
[NIDA], 2019; Substance Abuse and Mental Health Services Administration, 2018).
According to the Centers for Disease Control and Prevention (CDC), more than
11 million Americans admit to abusing opiates (CDC, 2016 para. 3). Medical providers
have recognized that the prescription of opiate-based pain medication has become a
significant health concern due to the high risk of addiction, over-dose related illnesses
and numerous deaths. As a result, providers and health care organizations have rushed to
change their prescribing habits based on the CDC’s directives, which detail the
appropriate management of opioid pain medications and list other medications that
should not be prescribed in conjunction with them (Clinical Advisor, 2016; Dowell,
Haegerich, & Chou, 2016). In response, some providers have drastically cut the number
of opiates they are prescribing, others have begun referring patients out to pain
management centers, while yet others have stopped prescribing opiates entirely
(Lagisetty, Healy & Garpestad, 2019). However, the documentation of all controlled
substances remains inconsistent.
Every state in the U.S. now has a law or regulation requiring the creation and use
of a prescription monitoring database (PDMD) for providers to track what controlled
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substances patients receive, how often, and from whom (Gudoski, 2015). Nationwide,
the comprehensiveness and usability of PDMDs appears to vary significantly (Davis,
2018; Gudoski, 2015; Inserro, 2018). The robustness of the databases has changed over
time with varying levels of impact on overdose-related illnesses and deaths (Smith et al.,
2019). Much closer to home, Missouri still does not have a functioning state-wide
PDMD (Erickson, 2019). This means that providers and organizations cannot track the
prescriptions of any particular patient across the state and may be unknowingly further
contributing to the crisis.
The purpose of this project was to implement a practice improvement change
which included the creation of a standardized form within an electronic medical record
(EMR) on which providers could document all aspects of controlled substance
monitoring. This template included dates/results of urine drug screens (UDS) and pill
counts, any concurrent Schedule II-IV prescriptions, and PDMD reviews. The PICOT
and project objectives are as follows: (p)opulation--providers in specified family
practice groups who prescribe controlled substances; (i)ntervention--implementation of
new controlled substance documentation template; (c)omparison--comparison of pretest
documentation frequency with post-test frequency; (o)utcomes--increased provider
documentation from pretest rate of less than 20%; and (t)ime--demonstrable
improvement in documentation compliance at 30 days and 60 days after implementation.
Literature Review
Healthcare provider education is centered on ensuring providers learn to properly
diagnose and treat illness and disease, but providers are often left to their own devices in
learning how to appropriately document that treatment (Balestra, 2017). Standard
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documentation, even with the advent and widespread use of EMRs, is still often limited
to the basics: exams, diagnosis, medication, dosage, procedures, referrals, and follow up
dates (Schneider, 2014). Except in very egregious circumstances, regulatory penalties
associated with substandard documentation are limited to fines and licensure penalties,
but do not normally result in criminal prosecution. However, even the perceived overprescription of opiates or other controlled substances may result in investigation by
insurance carriers, the Drug Enforcement Agency (DEA), or law enforcement (Schneider,
2014).
The existing literature focuses very heavily on the importance of patient
compliance and monitoring of individuals taking opiate-based pain medications and other
controlled substances. There are also numerous studies and articles with reams of data
indicating recommendations for appropriate prescribing of opiates in nearly every
population including geriatrics, adolescents, pregnant women, postoperative adults and
children. The literature supports the CDC recommendations for regular drug screens, pill
counts, avoidance of concurrent opiate-benzodiazepine or hypnotic prescriptions, and
regular checks of state-wide PDMD databases (Dowell, et. al, 2016). However, the
literature does not show that these tools have been particularly successful in reducing the
number of overdoses or overdose-related deaths (Davis, 2018; Inserro, 2018). Nor does it
adequately address the potential liability of prescribers associated with such adverse
outcomes (Kawi, 2016). Very recently, national news outlets published stories regarding
a physician found to be criminally liable in the overdose death of an opiate-addicted
patient; resulting in a life sentence for the physician (Associated Press, 2019). Part of the
case against this physician was predicated on the lack of an appropriate medical exam, no
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documentation of drug screening, no checks of the PDMD, and no medication reviews.
Most large organizations and private practices utilize some form of EMR, but
there is no consistent method for documenting controlled substances within any of them,
or method to transfer data across platforms. While the CDC guidelines from 2016 gave
suggestions and methods to more safely and appropriately prescribe opiates, there were
no recommendations for documentation standards. Primary source discussions about
effective methods for documenting the monitoring of opiates and other controlled
substances within an EMR continues to be limited (Hussain, Nelson, Polston & Zheng,
2019). The majority of the conversation surrounding the efficacy and deficiencies of the
existing methods is happening in blogs, online professional discussion boards, and
editorial articles, many of which are not formally published in scholarly journals. Nor
does there appear to be significant literature dedicated to addressing the need for
documentation that can be quickly reviewed and transmitted to other providers or
electronic systems. Since the opioid crisis remains front page news, and was even
mentioned by President Trump during the State of the Union Address (The White House,
2019), the likelihood of some form of regulatory ruling being issued by the DEA, Centers
for Medicare and Medicaid (CMS), or Office of the Surgeon General will only increase.
Poor documentation of monitoring tasks can be linked to barriers and challenges
experienced by providers in day-to-day practice (Davis, 2018; Kelly, 2014). In some
cases, organizations and providers were not fully utilizing all features of the EMR to ease
the burden of documentation. One example is providers not being able to electronically
prescribe (e-scribe) controlled substances. E-scribing provides an additional layer of
security, eliminating the risk of diversion by removing access to the providers’ DEA
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number on a written prescription or the ability to change the prescription (DEA, 2010).
Additional barriers include: lack of organizational policies, lack of a consistent
documentation format, data not being transferable amongst EMRs, separate logins for
each PDMD, and the need to check more than one PDMD for cities on state borders. The
inefficiency of the PDMDs is exacerbated by requiring providers to leave the EMR they
are working in, login to an entirely different system to complete searches (Kelly, 2014).
This lack of easily recognizable, reproducible, transmissible documentation increases the
likelihood that patients who are abusing or misusing controlled substances will not be
identified; thereby also increasing the medicolegal risks to the providers, practices, and
organizations.
According to Brummond, et al. (2017), the American Journal of Health-System
Pharmacy responded to the increasing risks and liability with recommendations that all
health care organizations develop a comprehensive framework for preventing the
diversion of controlled substance medications and improving documentation.
Developing a comprehensive framework for controlled substance management may be
easier said than done. Quality and process improvement initiatives can often be difficult
to implement, especially in larger organizations where there may be issues of complexity
and cost, questions of causality, policy or regulatory considerations, and substantially
differing opinions amongst stakeholders (Sollecito & Johnson, 2013). However, the
framework for appropriate documentation already exists in the form of guidelines for
prescribing and monitoring (CDC, 2016), existing PDMDs (Gudoski, 2015), and EMRs
that are capable of submitting controlled substance prescriptions electronically (DEA,
2010). The challenge will be to integrate the individually limited tools into a streamlined
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procedure that providers will find usable and implementable in daily practice.
The organization and practice group where this project took place had no existing
corporate policy to set the frequency of documenting drug screens, pill counts, and
checks of the PDMD; nor were there any specific tools to ensure consistent, reproducible,
researchable documentation of monitoring tasks within the EMR. This left the individual
providers to determine the most appropriate way to document, which may not be enough
to protect them or the organization from regulatory, civil, or criminal penalties. The goal
was to improve the documentation of identified providers and practices without losing
sight of the need to have improved outcomes for individual patients.
Framework
The framework for this project was the plan-do-study-act (PDSA) cycle which
provides a scientific method to apply single or multiple process changes to real-world
situations in an organizational setting once an aim has been set (Agency for Healthcare
Research and Quality [AHRQ], 2013; CMS, 2017). PDSA cycles allow for (P) planning
the method of observation and collection of data prior to the intervention, (D) initiation of
the intervention on a small scale, (S) analyzation of the pre and post intervention data,
(A) and determination of future actions based on the outcomes. The PDSA cycle was
originally developed for use in industrial processes, but has been shown to be amenable
to application in clinical settings (Upshaw, Steffen and McLaughlin, 2013).
Method
Design
This project was designed to be a quality process improvement. The problem was
identified as a barrier to health care providers utilizing the EMR to monitor controlled
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substance compliance. The goal was improvement in EMR documentation frequency
with respect to UDS and PDMD checks. Process change was implemented via creation
of a controlled substance template in the EMR. The proposed template was based on a
medication documentation tool for warfarin already available in the EMR.
Setting/Sample
The setting for this project consisted of four family practice offices with a total of
seven providers. The practices treat all age ranges--children, adult, adolescent and
geriatric patients. The samples included any chart with a controlled substance
prescription. The selected charts were chosen based on EMR-generated controlled
substance reports. The pretest sample size was 270 charts. The post-test samples were
188 charts and 201 charts at 30 and 60 days respectively. All charts meeting the criteria
within the given time frames were reviewed.
Approval Processes
Administrative approval was obtained from the director of clinical practice
management. The project plan and details were submitted to the DNP project
chairperson, capstone committee, and UMSL IRB for review and approved. IRB
approval was granted based on exemption category 4 as no patient risks were identified.
Potential benefits of the project included the reduction of provider and organizational risk
management profiles due to improved documentation. Ethical considerations of the
project included the avoidance of any identifying information and avoidance of a
perception of bias in data analysis.
Data Collection/Analysis
No identifiable data was collected on individual patients. Collected data was
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numerical only and applied to individual markers as to whether a UDS or PDMD check
was performed during the established timeframe. Data regarding pill counts and
concurrent Schedule II-IV prescriptions was excluded. The project focus was narrowed
to evaluate UDS and PDMD checks based on literature which identified those as most
useful in preventing overdose, misuse, and abuse. The resulting data was collated in
tables utilizing IBM Statistical Package for the Social Sciences (SPSS). Direct
comparisons of compliance data before and after implementation of the template was
utilized. Compliance data was reevaluated at 30 and 60 days after implementation. Sixmonth post-intervention data was collected and reviewed after completion of the project;
however, the results were not completed in time to be included here. Final results,
including the six-month post-test data, will be submitted to the organization for
evaluation and consideration of additional PDSA cycle implementation.
Procedures
The documentation tool was created by the corporate IT department and
integrated into the EMR. The new documentation process was implemented at all four
practice locations. Compliance rates were evaluated 30-days after implementation and
again at 60-days via EMR-generated controlled substance reports. Statistical analysis of
pretest and post-test data was completed using IBM SPSS software.
Planning
Organizational approval for this project was obtained. DNP committee and
university IRB committee approval obtained. Pretest rates of compliance were
established and evaluated. Post-test compliance was established and evaluated.
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Results
The purpose of this project was to evaluate provider documentation of controlled
substance monitoring. The question posed was whether providers would be more
compliant with documentation of controlled substance monitoring if they had a template
within the EMR. The data was based on retrospective chart reviews of seven family
practice providers from four offices. The data included pretest and post-test evaluations
of provider documentation of UDS and checks of the PDMD. Pill counts were not
included in the data collection as the providers stated pill counts were not part of their
routine compliance checks unless diversion/misuse was suspected.
The pretest data evaluated a 6-month time span from June 2018 through
December 2018. The initial report included 492 charts. Charts in which the patient
received a one-time only controlled substance prescription were eliminated. The final
chart reviews yielded 270 charts for pretest evaluation. Data was recorded as yes = 1, no
= 2 to answer whether or not the chart in question contained a UDS and/or a check of the
PDMD during the specified time period. The frequency distribution of the pretest data
indicated that UDSs were performed at a rate of 23.3% and PDMD checks were
performed at a rate of 9.3%, as illustrated in the frequency tables (see Appendix I).
Providers began using the new documentation template on April 11, 2019. The
first post-test data collection occurred 30 days later. The 30-day posttest chart reviews
were conducted in a similar manner to the pretest reviews. Charts with one-time only
controlled substance prescriptions were eliminated, yielding an N = 188. At the 30-day
mark the frequency distribution showed UDS were performed at a rate of 46.3% and
PDMD checks were performed at a rate of 17.6%, as illustrated in the 30-day posttest
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frequency table (see Appendix I). When compared to the pretest data via the use of the
Independent Samples Kruskal-Wallis Test, the null hypothesis for 30-day UDS is rejected
as p = .004, which is less than the .05 threshold (see Appendix II) representing a
statistical change in provider compliance. When comparing pre and post-test PDMD
checks, the means were also evaluated using the Independent Samples Kruskal-Wallis
Test. The findings were acceptance of the null hypothesis at 30-days with a p = .252 (see
Appendix II), indicating there was no statistically significant change in provider
compliance.
At the 60-day mark, the charts were again reviewed with the same exclusion
criteria previously established, yielding an N = 201. The frequency distribution at 60-days
reveals drug screens were performed at a rate of 19.9% and PDMD checks were
performed at a rate of 45.8% as found in the frequency tables (see Appendix I). The 60day data were then compared to the pretest data using the Independent Samples KruskalWallis test. The resulting 60-day UDS had a p = .339, affirming the null hypothesis and
indicating no change in provider compliance from the pretest comparison (see Appendix
II). At 60-days, the means were also evaluated with the Independent Samples KruskalWallis Test, yielding a nonsignificant p value of .505, again indicating no change to
provider compliance.
Discussion
In evaluating the pre and post-test comparisons, it was found that the null
hypothesis was rejected at 30 days for UDS checks, but accepted at the 60-day mark,
indicating there was improvement in documentation at 30-days, but not at 60-days. The
discrepancy in improvement can be explained by timing of the UDS. If a patient had a
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UDS at 30-days, they likely did not need one at the 60-day mark. It was also found that
the statistical evaluation for the PDMD checks at both the 30-day and 60-day marks was
not considered statistically significant despite a much higher frequency at both. Part of
the lack of statistical significance may be due to PDMD checks mostly occurring during
face-to-face encounters. A substantial number of the prescriptions were written as the
result of patient’s calling in for refills. Additionally, the 30-day, 60-day data only looked
at the dates matching those for written prescriptions.
Due to proprietary software constraints, the corporate IT team was unable to
create the documentation template as it was originally proposed. In order for the
template to be built as requested, the changes needed to be approved by the software
owners, then built by their application development team, likely at a substantial cost.
Despite multiple requests, no one from the EMR owner group was able to commit to
being interviewed for this project. Instead, the corporate IT team created a template to be
used in the physical exam portion of the chart. Feedback from the participating providers
indicated that they were forgetting to utilize the template during encounters because it
was not easily accessible, and they often had to go back to the encounter to document in
the template later. Having it only accessible during face-to-face encounters prevented
providers from utilizing the template for call-in refill requests. Providers also indicated
that the tool was “clunky” because it (a) required too much typing, (b) was only
accessible in the physical examination section of the EMR, (c) only accessible to the
providers, (d) was not easily found. Repeating the study with an improved, more
accessible template might yield different results. It might also be beneficial to add in
excluded monitoring tasks, such as checks for other scheduled medications, to further
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evaluate compliance.
Since completion of the project, the EMR has added additional functions making
it easier for providers to safely prescribe controlled substances. Providers can now
electronically prescribe all Schedule II-IV drugs. Patients no longer have to pick up their
prescriptions in person from the office, fewer prescriptions get lost/stolen, and providers
can be assured that the prescription they have written has not been altered in any way.
The EMR also now links directly with the state PDMD from the individual patient’s
chart, allowing the provider to see what controlled substances the patient is receiving,
from whom, when the prescriptions were written/filled, and the number of morphine
milligram equivalents (MMEs) the patient is receiving daily. The PDMD link also
contains a dashboard indicating how at-risk the patient is for overdose/misuse/abuse
based on the prescriptions they are receiving and the number of MMEs per day. Each
time the patient’s chart is opened, the PDMD link is immediately visible indicating when
the last check was performed and which provider checked it. It is likely that evaluation
of the same data at the 6-month mark will indicate a statistically significant improvement
in compliance as the tools are much easier access and utilize.
Conclusion
The participating providers showed substantial frequency improvement in
documentation at both the 30 and 60-day checks. Statistically, the only significant
improvement of their controlled substance monitoring was with UDS at 30-days. The
lack of statistical improvement in the PDMD checks may be attributed to the need to
leave the chart to check the database as well as lack of functionality in the template. It
may also have been due to the relatively small sample size and short time frame. The
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template that was created by the corporate IT team, was less than ideal for several
reasons: (a) only accessible in one section of the chart, (b) only accessible to the
providers, (c) required too much typing by providers, (d) was not searchable in the chart.
Based on the PDSA framework, the recommendation would be to abandon the current
template, have a new template created, and run the cycle again.
Despite the improved functionality of some tools since the end of the project,
there is still no single chart section or template where providers can document their
controlled substance monitoring tasks. When other areas of monitoring such as pill
counts and concurrent prescriptions of other scheduled medications are added, the need
for an easy to use template may become more obvious. While the template used for this
project was not ideal, it did set a framework for the type of template that might be
needed. Having accessible and effective documentation tools not only aids providers in
providing better, more appropriate care for their patients, but also reduces the risk of
liability for the individual providers and organizations.
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Appendix I: Frequency Distribution Tables
Pretest UDS
Frequency
Valid

Percent

Pretest PDMD
Valid

Cumulative

Percent

Percent

1

63

23.3

23.3

23.3

2

207

76.7

76.7

100.0

Total

270

100.0

100.0

Frequency
Valid

Valid

Percent

Valid

Cumulative

Percent

Percent

87

46.3

46.3

46.3

2

101

53.7

53.7

100.0

Total

188

100.0

100.0

Valid

Percent

25

9.3

9.3

9.3

2

245

90.7

90.7

100.0

Total

270

100.0

100.0

Frequency
Valid

Percent

Valid

Cumulative

Percent

Percent

1

33

17.6

17.6

17.6

2

155

82.4

82.4

100.0

Total

188

100.0

100.0

60-Day Posttest PDMD

60-Day Posttest UDS
Percent

Percent

30-Day Posttest PDMD

1

Frequency

Cumulative

1

30-Day Posttest UDS
Frequency

Percent

Valid

Valid

Cumulative

Percent

Percent

1

40

19.9

19.9

19.9

2

161

80.1

80.1

100.0

Total

201

100.0

100.0

Cumulative
Frequency
Valid

Percent

Valid Percent

Percent

1

92

45.8

45.8

45.8

2

109

54.2

54.2

100.0

Total

201

100.0

100.0
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Appendix II: Post-test Statistical Analysis (Nonparametric Tests)
Null Hypothesis
Comparison of 30-Day UDS
mean to Pretest UDS mean.

Test
Independent-Samples Median
Test

Significance
All test values are less than or
equal to the median.

Decision
Unable to compute.

Distribution of 30-Day UDS v
Pretest UDS.

Independent-Samples KruskalWallis Test

.004

Reject the null hypothesis.

Comparison of 60-Day UDS
mean to Pretest UDS.

Independent-Samples Median
Test

All test values are less than or
equal to the median.

Unable to compute.

Distribution of 60-Day UDS
mean to Pretest UDS.

Independent-Samples KruskalWallis Test

.339

Retain the null hypothesis.

Null Hypothesis
Comparison of 30-Day PDMD
mean to Pretest PDMD mean.

Test
Independent-Samples Median
Test

Significance
All test values are less than or
equal to the median

Decision
Unable to compute.

Distribution of 30-Day PDMD v
Pretest PDMD.

Independent-Samples KruskalWallis Test

.252

Retain the null hypothesis.

Comparison of 60-Day PDMD
to mean to Pretest PDMD
mean.

Independent-Samples Median
Test

All test values are less than or
equal to the median

Unable to compute.

Distribution of 60-Day PDMD v
Pretest PDMD

Independent-Samples KruskalWallis Test

.505

Retain the null hypothesis.

